136 related articles for article (PubMed ID: 9107663)
21. Recurrent rectal cancer and scar: differentiation with PET and MR imaging.
Ito K; Kato T; Tadokoro M; Ishiguchi T; Oshima M; Ishigaki T; Sakuma S
Radiology; 1992 Feb; 182(2):549-52. PubMed ID: 1732979
[TBL] [Abstract][Full Text] [Related]
22. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
Kim EE; Chung SK; Haynie TP; Kim CG; Cho BJ; Podoloff DA; Tilbury RS; Yang DJ; Yung WK; Moser RP
Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416
[TBL] [Abstract][Full Text] [Related]
23. PET scans of abdominal malignancy.
Blahd WH; Brown CV; Khonsary SA; Farahi JB; Quinones N; Ribe JY; Coyle JJ; Glass EC; Mandelkern MA
World J Surg; 1996 Feb; 20(2):245-7. PubMed ID: 8661826
[TBL] [Abstract][Full Text] [Related]
24. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of fluorine-18-deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study.
Langenhoff BS; Oyen WJ; Jager GJ; Strijk SP; Wobbes T; Corstens FH; Ruers TJ
J Clin Oncol; 2002 Nov; 20(22):4453-8. PubMed ID: 12431968
[TBL] [Abstract][Full Text] [Related]
26. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
Staib L; Schirrmeister H; Reske SN; Beger HG
Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
[TBL] [Abstract][Full Text] [Related]
27. Role of multidetector CT and FDG-PET/CT in the diagnosis of local and distant recurrence of resected rectal cancer.
Bellomi M; Rizzo S; Travaini LL; Bazzi L; Trifirò G; Zampino MG; Radice D; Paganelli G
Radiol Med; 2007 Aug; 112(5):681-90. PubMed ID: 17657420
[TBL] [Abstract][Full Text] [Related]
28. [Diagnosis of the postoperative local recurrence of rectal cancer by FDG-PET--a case report].
Katsumoto Y; Maruyama N; Nakamura M; Shingai T; Maruyama K; Nakaguchi K; Furukawa J; Okajima S; Sue F; Fukunaga H; Ikenaga M; Sekimoto K
Gan To Kagaku Ryoho; 2001 Oct; 28(11):1688-91. PubMed ID: 11708010
[TBL] [Abstract][Full Text] [Related]
29. [Value of positron emission tomography (18F-FDG-PET) in the diagnosis of recurrent rectal cancer].
Franke J; Rosenzweig S; Reinartz P; Höer J; Kasperk R; Schumpelick V
Chirurg; 2000 Jan; 71(1):80-5. PubMed ID: 10663007
[TBL] [Abstract][Full Text] [Related]
30. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose].
Römer W; Avril N; Dose J; Ziegler S; Kuhn W; Herz M; Jänicke F; Schwaiger M
Rofo; 1997 Jan; 166(1):62-8. PubMed ID: 9072107
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy.
Knight SB; Delbeke D; Stewart JR; Sandler MP
Chest; 1996 Apr; 109(4):982-8. PubMed ID: 8635381
[TBL] [Abstract][Full Text] [Related]
32. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
33. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
34. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
Frilling A; Tecklenborg K; Görges R; Weber F; Clausen M; Broelsch EC
Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
[TBL] [Abstract][Full Text] [Related]
35. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy.
Hofer C; Laubenbacher C; Block T; Breul J; Hartung R; Schwaiger M
Eur Urol; 1999; 36(1):31-5. PubMed ID: 10364652
[TBL] [Abstract][Full Text] [Related]
36. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
[TBL] [Abstract][Full Text] [Related]
37. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.
Ichiya Y; Kuwabara Y; Otsuka M; Tahara T; Yoshikai T; Fukumura T; Jingu K; Masuda K
J Nucl Med; 1991 Sep; 32(9):1655-60. PubMed ID: 1880564
[TBL] [Abstract][Full Text] [Related]
38. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
[TBL] [Abstract][Full Text] [Related]
40. FDG-PET/MRI in patients with pelvic recurrence of rectal cancer: first clinical experiences.
Plodeck V; Rahbari NN; Weitz J; Radosa CG; Laniado M; Hoffmann RT; Zöphel K; Beuthien-Baumann B; Kotzerke J; van den Hoff J; Platzek I
Eur Radiol; 2019 Jan; 29(1):422-428. PubMed ID: 29980927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
